July 15, 2021
Stemson Therapeutics announced today the closing of a DCVC Bio-led $15 million Series A financing to advance development of Stemson’s proprietary therapeutic solution to cure hair loss. Genoa Ventures, AbbVie Ventures and other investors join in supporting Stemson’s efforts to restore human hair growth with a novel cell regeneration technology using the patient’s own cells to generate new hair follicles.
See the press release
Read More »
July 15, 2021
It’s estimated over 60 million people in the US are losing their hair. At least 20% of them are under the age of 30, and more than 30% of women will experience noticeable hair loss.
Its root causes are diverse, from autoimmune conditions, to long-lasting chemotherapy effects, to scarring and injuries, to genetics and age-related conditions.
Regardless of the cause, for most people, losing their hair hits them very hard emotionally.
Read More »
November 10, 2020
Biotech innovator Stemson are scoping out research and development investments in the UK to develop a revolutionary cure for baldness in partnership with London-based Fortunis Capital as their lead investor in the country, it was announced today.
San Diego-based Stemson Therapeutics is developing technology to restore human hair growth with a novel approach using the patient’s own cells to generate new hair follicles.
Funding from impact investor Fortunis will support research and development of the product solution and position the UK as a leading contender to conduct human clinical trials,
Read More »
September 16, 2020
Stemson Therapeutics announced today a $7.5 million seed financing led by Allergan Aesthetics, an AbbVie Company, and impact investor Fortunis Capital to advance development of Stemson’s therapeutic solution to cure hair loss. Stemson aims to restore human hair growth with a novel approach using the patient’s own cells to generate new hair follicles.
See the press release
Read More »
September 14, 2020
Stemson Therapeutics announced approval in the United States of US patent No. 10716808, entitled “Methods and compositions to modulate hair growth” licensed exclusively from the Sanford Burnham Prebys Medical Discovery Institute. The patent covers a novel process developed by Stemson co-founder and Chief Scientific Officer, Alexey Terskikh, PhD, to differentiate Induced Pluripotent Stem Cells (iPSC) into dermal papilla cells, the cell type primarily responsible for controlling hair follicle generation and hair cycling. Issuance of this foundational patent provides stability surrounding the company’s efforts to develop its breakthrough iPSC-based solution for hair growth.
Read More »
September 8, 2020
Stemson Therapeutics is pleased to announce Meghan Samberg, PhD, joined our team as Vice President, R&D and Preclinical Development. Dr. Samberg will lead Stemson’s research and development efforts to prepare for human clinical trials of our hair growth cell therapy and will be responsible for helping drive regulatory and clinical strategy.
“Meghan brings extensive preclinical and clinical research experience and adds depth to the Stemson management team. Her expertise in tissue engineering strategies,
Read More »
September 11, 2019
Stemson Therapeutics is pleased to announce Cenk Sumen, PhD, will join our team as Chief Technology Officer. Dr. Sumen will lead Stemson’s manufacturing efforts to prepare for human clinical trials of our hair growth cell therapy and will be responsible for helping drive regulatory and clinical strategy. He will join Stemson’s executive team, reporting to Geoff Hamilton, Chief Executive Officer of Stemson, and will serve on the company Board of Directors.
“Cenk brings almost a decade of experience translating early stage cell therapy candidates into GMP compliant manufacturing environments.
Read More »
June 27, 2019
Today, Stemson Therapeutics announced a significant investment in its seed financing round by Allergan, a leading global pharmaceutical company. The investment will advance Stemson’s final product development in preparation for human clinical trials, and provide Allergan with a promising new product pipeline for its market leading Medical Aesthetics portfolio. The investment with Stemson represents Allergan’s first step into iPSC-based cell therapy technology. iPSC’s have the potential to become any cell type in the human body and hold great promise to deliver breakthrough regenerative medicine therapies in the future.
Read More »
June 26, 2019
Sanford Burnham Prebys scientist and Stemson Therapeutics Co-Founder demonstrates functional hair follicles grown from stem cells at International Society for Stem Cell Research (ISSCR) annual meeting.
Download the press release
Read More »
May 31, 2019
Sanford Burnham Prebys Medical Discovery Institute researchers Dr. Alexey Terskikh and Dr. Antonella Pinto have won a prize for best poster at the 2019 UC San Diego Division of Regenerative Medicine Symposium and a merit award for best abstract at the 2019 International Society for Stem Cell Research Annual Meeting. The poster and abstract highlighted the use of Dermal Papilla cells derived from human Induced Pluripotent Stem Cells (iPSC) to grow partially humanize de novo hair follicles in nude mice.
Read More »
